Biological Times Volume No. 5 | Issue No. 2 | Pages 4-6

Emerging Veterinary Biologics as Predictors of Human Immune Response: Epidemiological Evidence

Mahnoor Farrukh[1], Sidra Altaf[2] and Tasawar Iqbal[3]

1. Department of Epidemiology and Public Health, University of Agriculture Faisalabad, Pakistan
2. Department of Pharmacy, University of Agriculture Faisalabad, Pakistan
3. Institute of Physiology and Pharmacology, University of Agriculture Faisalabad, Pakistan

*Corresponding Author: **sidraltaf@uaf.edu.pk**

ABSTRACT

Veterinary biologics, including vaccines, immunomodulators, and monoclonal antibodies, are important tools to help predict the potential for immunity in humans from a One Health perspective. Using epidemiological data based on natural exposure allows for the approximate creation of human-like immunological responses that could not be obtained from clinical controlled trials. Data such as antibody kinetics, cellular activation, and correlates of immunity allow researchers to establish human immunological characteristics from studies in veterinary medicine. Comparative study of multiple species confirms that immunological pathways and biomarker systems for vaccine performance are conserved across species. Zoonotic disease case studies show the importance of veterinary investigations in determining potential human health risks and vaccine development. Despite species-specific differences, veterinary epidemiological data, along with systems immunology and predictive modeling, give accurate forecasts of immune responses.

Keywords: Veterinary biologics; Human immune response; Epidemiological evidence; One Health; Translational immunology; Comparative immunity

To cite this article: Farrukh M, S Altaf & T Iqbal. Emerging Veterinary Biologics as Predictors of Human Immune Response: Epidemiological Evidence. Biological Times. 2026. February 5(2): 4-6.

Introduction

Veterinary biologics include vaccines, monoclonal antibodies, cytokines, immune modulators, and other novel products containing biologically active ingredients that can be used to prevent or control diseases in animals. Veterinary Biologics focused primarily on the productivity of livestock, the well-being, and health of companion animals. They have evolved significantly, particularly with advances in Molecular Biology, Genomics, and Immunotechnology. Veterinary Biologics now utilizes many of the same platforms as those used in human medicine, including recombinant proteins, viral vectors, and nucleic acid-based vaccines. Animal immune responses can provide a unique perspective into predicting the immune response to immunological challenges in humans. The majority of infectious diseases affecting animals share similarities with humans in terms of the infective agent, mode of transmission, or immune response mechanism. By observing animal immune responses, the efficacy of an inoculation can be determined, as well as how long the immunity lasts, potential adverse effects, and the likelihood of human exposure before the general public receives an inoculation. Evidence derived from epidemiological studies conducted in settings where animals are exposed to a range of natural pathogenic agents is generally more informative than that obtained through studies of controlled trials. The objective of the current article is to compile information derived from epidemiological studies conducted in natural settings; evaluate the degree to which the information obtained in those studies can predict human immune responses; and present how this body of information will assist in translating the principles and practices applicable to human health and environmental protection in the context of the One Health initiative (1).

Conceptual Basis for Cross-Species Immune Prediction

The immunological makeup of mammalian species is similar, having identical architecture. Immunological receptors that sense innate immunity within mammals are conserved across species. The antigen-presenting system and the two major classes of components that mediate adaptive immunity, T and B lymphocytes (cells that produce antibodies or cytokines), are also conserved across the animal kingdom and represent the basis for comparing the immune systems of different species within these categories. Additionally, the use of similarities in core defense mechanisms within innate and adaptive immunity to formulate assumptions and predictions about different mammalian species is further strengthened, as these mechanisms have survived evolutionarily and provide an advantage for survival. Species may have adapted to a specific environment or situation, but their basic approach to protect against disease remains comparable. One Health integration of animal, human, and environmental health concepts recognizes that immunological responses cannot be understood solely based on the differences in individual species' responses. Therefore, to make accurate predictions about the immune system's response to a potential human disease, veterinary-immunological information is essential (2).

Overview of Emerging Veterinary Biologics

In recent years, the veterinary biological products industry has been seeing dramatic improvements and innovations as a result of new vaccine technologies. The introduction of recombinant subunit, viral-vectored, and mRNA-based vaccines illustrates how far veterinary medicine has come in the last few years because of the advancements in human vaccinology. Innovations in vaccine technology represent enhancements and refinements in antigen safety, precision, and immune specificity across species. The use of monoclonal antibodies and immune-modulating agents in the treatment of animal health has greatly expanded recently (3). Advancements in adjuvant systems, new delivery systems such as nanoparticles, mucosal methods of administration, and the production of long-acting formulations have improved the ability of these products to consistently induce a potent and long-lasting immune response to a particular infectious disease agent following vaccination. The immunologic information thus generated facilitates the development of other human intended vaccine and therapeutic products.

Epidemiological Evidence from Veterinary Populations

Field Trials and Population-Level Data

Extensive epidemiological data regarding immune responses in a genetically diverse population can be obtained from a large-scale vaccination program for livestock and companion animals, showing the variability pattern of the immune response, the effectiveness of vaccinations, and herd immunity thresholds. The long-term safety and efficacy of vaccines can be captured through the use of a post-marketing surveillance system, which collects information about the durability of immunity and the occurrence of rare adverse events.

Zoonotic Disease Control as a Natural Experiment

The vaccination of animals against zoonotic diseases (e.g., rabies, human vaccine-related influenza, brucellosis, and coronaviruses) is a natural experiment for testing the prediction of immunity. The decreased incidence of human disease as a result of animal vaccination provides evidence for the indirect protective effect of veterinary biologics. The close timing of increased animal vaccination coverage with the decreased occurrence of human spillover events gives evidence of how the immune modulation occurring within animals can serve to predict and influence the risk of human diseases.

Adverse Immune Events and Safety Signals

Adverse immune events, e.g., immune pathologies, antibody-dependent enhancement, autoimmune reactions, and hypersensitivity responses, have been reported as a result of the use of veterinary biologics. Early identification of these adverse immune responses occurring in animals serves as an important safety signal that can assist in the development of human biologics. Such findings provide input for the refinement of antigen design, the selection of vaccine dosage strategies, and the choice of adjuvants before widespread human exposure.

Comparative Immunogenicity and Immune Signatures

Biomarkers for immune activation are common to different species by means of Comparative immunology and include neutralizing antibody titer level, cytokine profile, cellular immune markers, giving the potential for a "measurable continuum" between human and veterinary immune responses. Research into the dynamics of cytokines, antibody kinetics, and T-cell responses shows that both immune magnitude and persistence are similar between vaccinated and infected individuals(4). Such similarities help to reinforce confidence in the ability of veterinary studies to predict potential outcomes in humans. Employing systems immunology and omics techniques (transcriptomics, proteomics, and metabolomics) to characterize immune responses is the equivalent of mapping immune responses across species. The epidemiological application of these data has demonstrated that there are conserved immune pathway networks that are of interest from a translational perspective.

Case Studies from veterinary biologics with their Translational Relevance

Veterinary biologics case studies provide critical evidence for their translational value in the prediction of human immune responses. Animals serve as both natural and intermediate reservoirs for pathogens infecting humans as well, making veterinary populations highly insightful for how to create optimal vaccines, understanding immune protection, disease epidemiology, and progression.

Zoonotic Viral Diseases

Zoonotic viral disease such as influenza and coronaviruses provides an unprecedented opportunity for understanding immune relevance in vivo between species. Examples include how veterinary surveillance of avian and swine influenza has provided invaluable information about the selection of antigens, the evolution, and the immune escape mechanism of strains in humans, to develop better human vaccines. Understanding the immune responses in animals infected with coronaviruses provides critical information about how viruses transmit, how long antibodies remain effective, and how the immune response protects against reinfection. Data obtained is used to conduct early risk assessments and to design vaccine platforms to be used in humans.

Parasitic and Bacterial Disease Models with Human Parallels

Veterinary models of parasitic and bacterial diseases, such as helminth infections, tuberculosis, and brucellosis, show very similar immunopathological features of these livestock diseases in humans (3). Studies reveal host-pathogen interactions, mechanisms of immune regulation, and the correlates of protection in livestock with these infections, which inform better strategies for human vaccine creation and immunotherapy.

Methodological Approaches in Veterinary Immunoepidemiology

Veterinary immunoepidemiology has been studied in a variety of ways through different types of research proposals, including surveillance systems, cohort studies, and ecological studies (5). These methodologies are used to provide a long-term evaluation of the dynamics of immune health and disease over time. Combining data from the fields of veterinary medicine and human health has the potential to create avenues for researchers to compare large sets of data across both systems for identifying possible trends or early warning signs that could be of importance for both healthcare sectors. The use of harmonized surveillance practices improves the accuracy of predictive analysis within each of the two respective systems - veterinary and human health. The application of predictive modeling and machine learning technologies for examining and predicting risk associated with all forms of veterinary immunologic monitoring indicators creates opportunities to develop actionable plans for future human health.

Translational and Public Health Implications

Veterinary immune surveillance, immune response patterns, adverse events, and vaccine efficacy assist in an early warning system for public health issues in animals and humans. The recognition of waning immunity, antigenic drift through viral evolution, and immune escape mechanisms in animal populations may indicate an impending issue with similar conditions for humans. Veterinary vaccination programs data guide clinical trial design in humans by informing the selection of antigen, dosing schedules, and routes of delivery. The immune variability at the animal population level assists with anticipating diversity of human responses, enhancing trial stratification and risk assessment, resulting in reduced uncertainty in early-phase human studies. Integrating veterinary immunological data into public health planning strengthens pandemic preparedness, particularly for zoonotic diseases.

Table 1: Translational Relevance of Veterinary Biologics in Predicting Human Immune Responses

Veterinary Biologic Type	Target Animal Population	Immune Response Observed	Epidemiological Evidence Source	Relevance to Human Immune Prediction
Recombinant viral vaccines	Poultry	Neutralizing antibody production	Field vaccination surveillance	Predicts vaccine-induced humoral immunity
Vector-based vaccines	Swine	T-cell–mediated immunity	Cohort studies during outbreaks	Informs cellular immune protection
mRNA vaccine platforms	Companion animals	Rapid antibody kinetics	Post-vaccination monitoring	Early assessment of response durability
Inactivated bacterial vaccines	Cattle	Th1-biased immune response	Natural exposure studies	Models immune control of bacterial infections
Live attenuated vaccines	Small ruminants	Long-term immune memory	Longitudinal epidemiological data	Predicts immune persistence in humans
Monoclonal antibodies	Dogs	Targeted immune modulation	Clinical veterinary trials	Guides therapeutic antibody development

Limitations and Sources of Uncertainty

Despite many shared features among immune systems, there are significant species divergences associated with immunity. In addition, there are several features that create differences in immune response magnitude and duration, including differences in expression of receptors, regulation of the immune response, and lifespan. Additionally, several types of confounding variables, including but not limited to environmental, genetic, and management factors (e.g., nutrition, housing conditions, previous exposure to pathogens), exist and complicate the interpretation of veterinary research. Finally, results obtained using animals may be at risk of over-extrapolating to humans if validation studies are not performed.

Future Directions and Research Priorities

Systems immunology and Artificial Intelligence have facilitated collaboration between disciplines to create computational models able to define and predict the molecular signatures associated with molecular diversity across species, accelerating the identification of viral strains responsible for zoonotic transmission. This means we will likely be able to identify, develop, and provide improved responses to the emergence and re-emergence of "novel" and "re-emerging" zoonotic pathogens via the use of veterinary biological products as "early warning systems. The development of global One Health initiatives has expanded our ability to gather, assess, and share real-time data regarding the health of animal populations, their immune responses, and their likelihood of transmitting zoonotic diseases to humans. These systems provide an excellent opportunity to forecast trends within animal and human populations via predictive epidemiological information. Furthermore, identification of animal data and the analysis of the resulting slides via current statistical methodologies can better assess risk, identify timely intervention strategies, and assist in designing personalized and precise vaccination strategies for humans based on the immune correlates of protection and variability in which individuals respond to vaccines.

Conclusion

Veterinary biologics are becoming a new powerful resource for predicting human immune responses to emerging infectious diseases using real-world epidemiological data. Animal populations exposed to natural environmental forces will have different immune outcomes due to the variations in genetics and the diverse range of exposure types. The growing body of comparative literature has demonstrated that common biomarkers of immune responses and a similar pattern of immune response can be seen in both humans and animals. While it is important to interpret the data with caution due to specific immune responses of different species, the potential translational value of veterinary evidence can be maximized by applying it using the One Health approach. The combination of veterinary epidemiology, systems immunology, advanced analytics, and cross-sectoral surveillance can improve predictive accuracy and reduce uncertainty in forecasting human immune responses, resulting in efficient use of the best available evidence-based approaches to developing immunological solutions for humans.

References

[1] Aida V, Pliasas VC, Neasham PJ, North JF, McWhorter KL, Glover SR, et al. Novel Vaccine Technologies in Veterinary Medicine: A Herald to Human Medicine Vaccines. Front Vet Sci [Internet]. 2021 Apr 15 [cited 2026 Jan 26];8:654289. Available from: www.frontiersin.org

[2] Entrican G, Lunney JK, Wattegedera SR, Mwangi W, Hope JC, Hammond JA. The Veterinary Immunological Toolbox: Past, Present, and Future. Front Immunol [Internet]. 2020 Jul 28 [cited 2026 Jan 26];11:558720. Available from: www.frontiersin.org

[3] Saalmueller A, Guzman E, Binder CJ, IJsbrand Reyneveld G, J Savelkoul HF, Parmentier HK. Current understanding of natural antibodies and exploring the possibilities of modulation using veterinary models. A review. frontiersin.org [Internet]. 2020 Sep 10 [cited 2026 Jan 23];11:2139. Available from: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.02139/full

[4] Garcia-Fogeda I, Besbassi H, Larivière Y, Ogunjimi B, Abrams S, Hens N. Within-host modeling to measure dynamics of antibody responses after natural infection or vaccination: A systematic review. Vaccine [Internet]. 2023;41(25):3701–9. Available from: https://doi.org/10.1016/j.vaccine.2023.04.030

[5] Saad-Roy CM, Morris SE, Boots M, Baker RE, Lewis BL, Farrar J, et al. Impact of waning immunity against SARS-CoV-2 severity exacerbated by vaccine hesitancy. PLoS Comput Biol [Internet]. 2024;20(8 August):1–18. Available from: http://dx.doi.org/10.1371/journal.pcbi.1012211.